Patents by Inventor Sarah Wulhfard
Sarah Wulhfard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11629199Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Inventors: Laura Gualandi, Sarah Wulhfard, Francesca Pretto, Catherine Pemberton-Ross, Alessandra Villa, Roberto De Luca
-
Patent number: 11274133Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.Type: GrantFiled: April 12, 2019Date of Patent: March 15, 2022Assignee: PHILOGEN S.P.A.Inventors: Roberto De Luca, Francesca Pretto, Sarah Wulhfard
-
Publication number: 20210369857Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.Type: ApplicationFiled: July 23, 2021Publication date: December 2, 2021Applicant: PHILOGEN S.P.A.Inventors: Dario Neri, Roberto De Luca, Sarah Wulhfard
-
Patent number: 11103592Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.Type: GrantFiled: November 8, 2017Date of Patent: August 31, 2021Inventors: Dario Neri, Roberto De Luca, Sarah Wulhfard
-
Patent number: 10906963Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.Type: GrantFiled: April 12, 2017Date of Patent: February 2, 2021Assignee: Philogen S.P.AInventors: Rémy Gébleux, Sarah Wulhfard
-
Publication number: 20200270322Abstract: This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the A1 domain of tenascin C or the ED-A or ED-B isoforms of fibronectin. The antibody molecules may be positioned at the N and C terminals of the IL4. The immunoconjugate may be useful in the treatment of cancer, inflammatory autoimmune disease and other disease characterised by expression of an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling.Type: ApplicationFiled: October 12, 2017Publication date: August 27, 2020Inventors: Mattia Matasci, Francesca Pretto, Sarah Wulhfard
-
Publication number: 20200165326Abstract: The present invention relates to fusion proteins comprising a growth factor linked to the N-terminus of an antibody via a linker peptide, in particular, wherein said growth factor iS IGF-1 and said antibody is directed against collagen.Type: ApplicationFiled: February 20, 2018Publication date: May 28, 2020Inventors: Sarah Wulhfard, Mattia Matasci
-
Patent number: 10647760Abstract: The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.Type: GrantFiled: December 9, 2016Date of Patent: May 12, 2020Assignee: PHILOGEN S.P.A.Inventors: Sarah Wulhfard, Alessandra Villa, Catherine Pemberton Ross, Francesca Pretto, Filippa Fleetwood
-
Publication number: 20200061203Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.Type: ApplicationFiled: November 8, 2017Publication date: February 27, 2020Inventors: Dario Neri, Roberto DeLuca, Sarah Wulhfard
-
Publication number: 20190375837Abstract: This invention relates to methods and compositions, in a combination therapy, for treatment of neoplastic disease, including tumors and cancer, wherein an immunocytokine and a small molecule drug conjugate which comprises a moiety capable of binding to a tumor-associated target, e.g., capable of binding to carbonic anhydrase IX (CAIX), are administered. In preferred embodiments, the immunocytokine comprises an antibody targeting the ED-B or ED-A domain of fibronectin and interleukin-2, and the small molecule drug conjugate comprises a ligand moiety capable of binding to CAIX, a linker, and a cytotoxic drug.Type: ApplicationFiled: February 23, 2018Publication date: December 12, 2019Applicant: PHILOGEN SPAInventors: Dario NERI, Samuele CAZZAMALLI, Sarah WULHFARD, Francesca PRETTO
-
Publication number: 20190284253Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.Type: ApplicationFiled: April 12, 2019Publication date: September 19, 2019Inventors: Roberto DE LUCA, Francesca PRETTO, Sarah WULHFARD
-
Patent number: 10308696Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.Type: GrantFiled: May 5, 2016Date of Patent: June 4, 2019Assignee: PHILOGEN S.P.A.Inventors: Roberto De Luca, Francesca Pretto, Sarah Wulhfard
-
Publication number: 20190127451Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.Type: ApplicationFiled: April 12, 2017Publication date: May 2, 2019Inventors: Rémy Gébleux, Sarah Wulhfard
-
Publication number: 20190062414Abstract: The invention relates to the diagnosis and treatment of diseases,including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.Type: ApplicationFiled: December 9, 2016Publication date: February 28, 2019Inventors: Sarah Wulhfard, Alessandra Villa, Catherine Pemberton Ross, Francesca Pretto, Filippa Fleetwood
-
Patent number: 10098976Abstract: The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind: i) the IIICS isoform of fibronectin, ii) matrix-metalloproteinase 3 (MMP3), iii) periostin, or iv) tenascin-W.Type: GrantFiled: July 28, 2015Date of Patent: October 16, 2018Assignee: Philogen S.P.A.Inventors: Laura Gualandi, Sarah Wulhfard, Catherine Hutchinson, Mattia Matasci
-
Publication number: 20180079793Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.Type: ApplicationFiled: May 5, 2016Publication date: March 22, 2018Inventors: Roberto DE LUCA, Francesca PRETTO, Sarah WULHFARD
-
Patent number: 9580485Abstract: Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient.Type: GrantFiled: July 24, 2012Date of Patent: February 28, 2017Assignee: Philogen S.p.A.Inventor: Sarah Wulhfard
-
Publication number: 20140170109Abstract: Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient.Type: ApplicationFiled: July 24, 2012Publication date: June 19, 2014Applicant: Philogen S.p.AInventor: Sarah Wulhfard
-
Publication number: 20080145893Abstract: Recombinant proteins are of great commercial interest. Yet, most current production methods in mammalian cells involve the time- and labor-consuming step of creating stable cell lines. Production methods based on transient gene expression are advantageous in terms of speed and versatility, yet, thus far, those methods have not shown the specific productivity, batch yield and volumetric yield to be an economic alternative to stable cell lines. The inventors improved on the methodology of transient transfection and achieved commercially relevant yields in terms of specific productivity (exceeding 35 pg per cell per day), batch yield (exceeding 700 mg/l) and volumetric yield.Type: ApplicationFiled: September 17, 2006Publication date: June 19, 2008Applicant: EXCELLEGENE SAInventors: Markus Hildinger, Sarah Wulhfard, Gaurav Backliwal, David Hacker, Maria De Jesus, Florian Maria Wurm